Findings of a new study into pericytes — cells with multiple functions including immune cell regulation — suggest that targeting a protein known as HIF-2alpha, which is involved in the response to low oxygen conditions, or hypoxia, may be a potential therapeutic approach for pulmonary arterial hypertension (PAH). The…
Researchers have identified two inflammation-related genes — SELE and CCL20 — whose activity could serve as diagnostic biomarkers for the development of pulmonary hypertension (PH) in people with COVID-19. Further, the team also identified molecules that target these biomarkers as possible therapeutic approaches for managing the complication. Overall, the…
Reduced exercise capacity appeared to be a consequence of cardiac and pulmonary changes, but not skeletal muscle alterations, in rat models of pulmonary hypertension (PH), according to recent research. While no functional problems with muscles could be observed despite obvious impairments in exercise capacity, significant cardiopulmonary dysfunction was already present.
The U.S. Food and Drug Administration (FDA) has supported Inhibikase Therapeutics’ Phase 2/3 trial of its experimental formulation of imatinib, called IkT-001Pro, for pulmonary arterial hypertension (PAH), the company reports. In a meeting, the FDA asked the company to complete a preclinical study in cells to compare…
A noninvasive intervention that makes use of ultrasound to target the splenic nerve — a nerve in the spleen, an organ in which immune cells develop — was found to reduce inflammation and the severity of pulmonary arterial hypertension (PAH) in rat models of the disease, according to a…
Chiesi Group has reached an agreement with Gossamer Bio to develop and market seralutinib for certain types of pulmonary hypertension (PH). The agreement seeks to support the therapy’s ongoing testing in pulmonary arterial hypertension (PAH) and to accelerate its development for pulmonary hypertension associated with…
A diet poor in two amino acids called glutamine and serine may improve the health of pulmonary blood vessels and reduce the progression of pulmonary hypertension (PH), according to a recent study. Specifically, researchers found that these amino acids are used by cells in blood vessels to produce other…
Tenax Therapeutics has been granted another U.S. patent for levosimendan, this one covering all three routes of administration and its active metabolites, for the treatment of people with PH-HFpEF, or pulmonary hypertension and heart failure with preserved ejection fraction. Issued by the U.S. Patent and Trademark Office, the…
Low levels of PM20D1, a molecule involved in metabolizing lipids, were identified as a risk factor for mortality in people with pulmonary arterial hypertension (PAH), a study reports. As a result, PM20D1, or peptidase M20 domain containing 1, may be a biomarker of disease prognosis, according to scientists. Lipid…
Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in people with HIV-1 infection in a bioinformatics study, offering new perspectives to uncover the underlying molecular mechanisms that link HIV infection and PAH. The genes ISG15 and IFI27 are established hub genes involved in the type…
More than 80 organizations globally, including the U.S.-based Pulmonary Hypertension Association (PHA), will unite on May 5 for World Pulmonary Hypertension Day, celebrated annually to heighten awareness of pulmonary hypertension (PH), which affects an estimated 75 million people worldwide. This year’s global initiative is led by PHA Europe,…
MACC1, a gene that’s been linked to overgrowth of cancer cells, is more active in the lungs of people with pulmonary arterial hypertension (PAH) than in healthy individuals, a study out of China found, suggesting it could be used as a diagnostic biomarker for the disease. Researchers also observed…
Get regular updates to your inbox.